Cargando…
The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge
OBJECTIVES: More than a quarter of single-country systemic lupus erythematosus (SLE) interventional randomized clinical trials (RCTs) were conducted in China. To help develop management guidelines and set benchmarks for future SLE research, a systematic review of current trials is needed. METHODS: W...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035534/ https://www.ncbi.nlm.nih.gov/pubmed/35479089 http://dx.doi.org/10.3389/fimmu.2022.848478 |
_version_ | 1784693313544126464 |
---|---|
author | Tian, Jingru Zhou, Hang Liu, Juan Xiong, Feng Yi, Ping Cao, Pengpeng Fang, Dorthy Zhang, Bo Lu, Qianjin |
author_facet | Tian, Jingru Zhou, Hang Liu, Juan Xiong, Feng Yi, Ping Cao, Pengpeng Fang, Dorthy Zhang, Bo Lu, Qianjin |
author_sort | Tian, Jingru |
collection | PubMed |
description | OBJECTIVES: More than a quarter of single-country systemic lupus erythematosus (SLE) interventional randomized clinical trials (RCTs) were conducted in China. To help develop management guidelines and set benchmarks for future SLE research, a systematic review of current trials is needed. METHODS: We searched systematically three databases and four registries to summarize the interventional RCTs in mainland China and identify factors associated with participant loss. The internal validity of trials was assessed using the Cochrane risk-of-bias tool for assessing risk of bias. The odds ratio (OR) was defined as the ratio of the odds of less than 10% loss to follow-up in the presence or absence of different factors. RESULTS: A total of 188 trials met our inclusion criteria, and 15·5% of trials conducted in mainland China ranked low risk of bias. Participant loss was significantly higher among trials that had a defined primary outcome or were registered {primary outcome identification (0·02 [0·00-0·23]) and registration (0·14 [0·03-0·69])}. Trials examining traditional Chinese medicine (TCM) pharmacological treatments had an 8·16-fold (8·16 [1·28-51·98]) higher probability of having low participant loss than trials examining non-TCM pharmacological treatment trials, and trials that did not report masking status had a 15·95-fold (15·95 [2·45-103·88]) higher probability of having low participant loss than open-label trials. In addition, published articles in Chinese also had higher probability of having low participant loss (5·39 [1·10-26·37]). CONCLUSION: SLE trials conducted in mainland China were of relatively poor quality. This situation, including nonrigorous design, lack of registration, and absence of compliance reporting, needs to be ameliorated. To maintain the fundamental repeatability and comparability of mainland China SLE RCTs, transparency of the clinical trial process and complete reporting of the trial data are crucial and urgently needed. |
format | Online Article Text |
id | pubmed-9035534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90355342022-04-26 The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge Tian, Jingru Zhou, Hang Liu, Juan Xiong, Feng Yi, Ping Cao, Pengpeng Fang, Dorthy Zhang, Bo Lu, Qianjin Front Immunol Immunology OBJECTIVES: More than a quarter of single-country systemic lupus erythematosus (SLE) interventional randomized clinical trials (RCTs) were conducted in China. To help develop management guidelines and set benchmarks for future SLE research, a systematic review of current trials is needed. METHODS: We searched systematically three databases and four registries to summarize the interventional RCTs in mainland China and identify factors associated with participant loss. The internal validity of trials was assessed using the Cochrane risk-of-bias tool for assessing risk of bias. The odds ratio (OR) was defined as the ratio of the odds of less than 10% loss to follow-up in the presence or absence of different factors. RESULTS: A total of 188 trials met our inclusion criteria, and 15·5% of trials conducted in mainland China ranked low risk of bias. Participant loss was significantly higher among trials that had a defined primary outcome or were registered {primary outcome identification (0·02 [0·00-0·23]) and registration (0·14 [0·03-0·69])}. Trials examining traditional Chinese medicine (TCM) pharmacological treatments had an 8·16-fold (8·16 [1·28-51·98]) higher probability of having low participant loss than trials examining non-TCM pharmacological treatment trials, and trials that did not report masking status had a 15·95-fold (15·95 [2·45-103·88]) higher probability of having low participant loss than open-label trials. In addition, published articles in Chinese also had higher probability of having low participant loss (5·39 [1·10-26·37]). CONCLUSION: SLE trials conducted in mainland China were of relatively poor quality. This situation, including nonrigorous design, lack of registration, and absence of compliance reporting, needs to be ameliorated. To maintain the fundamental repeatability and comparability of mainland China SLE RCTs, transparency of the clinical trial process and complete reporting of the trial data are crucial and urgently needed. Frontiers Media S.A. 2022-04-11 /pmc/articles/PMC9035534/ /pubmed/35479089 http://dx.doi.org/10.3389/fimmu.2022.848478 Text en Copyright © 2022 Tian, Zhou, Liu, Xiong, Yi, Cao, Fang, Zhang and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tian, Jingru Zhou, Hang Liu, Juan Xiong, Feng Yi, Ping Cao, Pengpeng Fang, Dorthy Zhang, Bo Lu, Qianjin The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge |
title | The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge |
title_full | The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge |
title_fullStr | The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge |
title_full_unstemmed | The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge |
title_short | The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge |
title_sort | systemic lupus erythematosus interventional trials in mainland china: a continuous challenge |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035534/ https://www.ncbi.nlm.nih.gov/pubmed/35479089 http://dx.doi.org/10.3389/fimmu.2022.848478 |
work_keys_str_mv | AT tianjingru thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT zhouhang thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT liujuan thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT xiongfeng thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT yiping thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT caopengpeng thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT fangdorthy thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT zhangbo thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT luqianjin thesystemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT tianjingru systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT zhouhang systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT liujuan systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT xiongfeng systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT yiping systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT caopengpeng systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT fangdorthy systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT zhangbo systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge AT luqianjin systemiclupuserythematosusinterventionaltrialsinmainlandchinaacontinuouschallenge |